Bimiralisib - PIQUR Therapeutics

Drug Profile

Bimiralisib - PIQUR Therapeutics

Alternative Names: PQR-309

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PIQUR Therapeutics
  • Class Antineoplastics; Small molecules; Triazines
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Lymphoma
  • Phase I/II Breast cancer
  • Phase I Solid tumours
  • Preclinical Brain disorders; Eye-Disorders; Skin cancer; Skin disorders

Most Recent Events

  • 22 May 2018 Bimiralisib is still in phase I trials for Solid-tumours in Switzerland and USA (NCT02483858)
  • 01 May 2018 PIQUR Therapeutics completes a phase I trial in Solid tumours in Spain, Switzerland, United Kingdom, USA (PO) (NCT02483858)
  • 01 Apr 2018 PIQUR Therapeutics completes a phase II trial in Lymphoma (Second-line therapy or greater) in United Kingdom, Belgium, USA, Spain, Germany, Switzerland (PO) (NCT02669511) (EudraCT2015-001306-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top